HC Wainwright Decreases Earnings Estimates for MediWound

Posted by Stanley Muller on May 29th, 2026

MediWound Ltd. (NASDAQ:MDWD – Free Report) – HC Wainwright cut their FY2030 earnings per share (EPS) estimates for shares of MediWound in a report issued on Thursday, May 28th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings of $3.11 per share for the year, down from their previous estimate of $3.21. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.75) per share.

A number of other research analysts have also weighed in on the stock. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Tuesday, April 21st. Finally, Oppenheimer reissued an “outperform” rating and issued a $32.00 target price (down from $33.00) on shares of MediWound in a research note on Wednesday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $34.00.

Get Our Latest Analysis on MediWound

MediWound Price Performance

MDWD opened at $14.56 on Friday. The company’s 50 day simple moving average is $16.68 and its two-hundred day simple moving average is $17.46. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The firm has a market capitalization of $187.10 million, a price-to-earnings ratio of -6.44 and a beta of 0.21.

MediWound (NASDAQ:MDWD – Get Free Report) last released its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. MediWound had a negative net margin of 180.30% and a negative return on equity of 68.75%. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $3.37 million. During the same period last year, the company posted ($0.07) EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MDWD. Rhumbline Advisers raised its position in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 481 shares during the period. Russell Investments Group Ltd. raised its position in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the period. BNP Paribas Financial Markets raised its position in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the period. Finally, Quarry LP purchased a new stake in MediWound in the fourth quarter valued at approximately $26,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.